The authors demonstrated that recombinant IL-9 (rIL-9) enhanced the anti-cancer activity of anti-PD-1 treatment (pembrolizumab) ex vivo by inducing a cytotoxic response in CD8 TILs. The gene discussed is IL9; the disease is cancer.